INS SINGLE-INGREDIENT ANTIHISTAMINES
First-Line Nasal Allergy Treatment
Allergic Rhinitis and its Impact on Asthma (ARIA) treatment guidelines, issued in partnership with the World Health Organization, recommend INS treatments like Flonase® Allergy Relief as first-line treatment for allergic symptoms, calling them “the most effective drugs.”13,14
Canadian guidelines recommend INS treatments for moderate to severe intermittent symptoms or mild persistent rhinitis alone or in combination with antihistamines.15
INS treatments are recognized as the most effective, long-term treatment options for allergic symptoms.13 Flonase® Allergy Relief has been approved for year-round use. After 3 months of daily use, patients should ask their doctor if they can continue using Flonase® Allergy Relief.7
Ask your patients how well their allergic rhinitis symptoms are controlled
A patient survey showed that 60% of nasal allergy sufferers were not fully satisfied with their current allergy medication.16 Some may need to try another nasal allergy treatment to see if they can get better relief.
Flonase Allergy Relief is applied directly in the nose and relieves nasal congestion.1,7-10 In addition to relieving nasal allergy symptoms, Flonase® Allergy Relief is an intranasal corticosteroid (INS)‡ shown to relieve nasal allergy symptoms and itchy, watery eyes without a prescription.§7,17 Symptom relief starts with the first dose for some patients.7,17
- Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy. 2008;63(10):1292-1300.
- Hallgren J, Pejler G. Biology of mast cell tryptase: an inflammatory mediator. FEBS J. 2006;273(a):1871-1895.
- Broide D. The pathophysiology of allergic rhinoconjunctivitis. Allergy Asthma Proc. 2007;28(4):398-403.
- Antihistamines for allergies: WebMD website. http://www.webmd.com/allergies/guide/antihistamines-for-allergies. Accessed November 20, 2014.
- IGE’s role in allergic asthma. Asthma and Allergy Foundation of America website. https://www.aafa.org/display.cfm?id=8&sub=16&cont=54. Accessed June 2, 2014.
- Antihistamines for allergies: WebMD website. http://www.webmd.com/allergies/guide/antihistamines-for-allergies. Accessed November 20, 2014
- Flonase® Allergy Relief Product Monograph. GlaxoSmithKline Consumer Healthcare Inc. August 23, 2016.
- Claritin Product Monograph. Bayer Inc. December 17, 2014.
- Reactine Product Monograph. McNeil Consumer Healthcare. June 11, 2014.
- Allegra Product Monograph. Sanofi-Aventis Canada Inc. September 8, 2006.
- Nasacort Allergy 24HR/Nasacort AQ Product Monograph. Sanofi-Aventis Canada Inc. December 11, 2013.
- Nasacort Package Leaflet. Cheshire, UK: Aventis Pharma, 2016.
- Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update. Allergy. 2008;63(suppl 86):8-160.
- Shinkwin CA. Guidelines in the management of allergic rhinitis [slide presentation]. Bon Secours GP Study Day. Presented January 28, 2012. http:www.bonsecours.ie/contentfiles/GP%20and%20Consultants/ALLERGIC%20RHINITIS1.ppt. Accessed December 17, 2014.
- Small P, Frenkiel S, Becker A, et al. Rhinitis: an executive summary of a practical and comprehensive approach to assessment and therapy. J Otolaryngol. 2007;36(Suppl 1);S1-S27.
- GSK data on file. GSK Consumer Healthcare announces Flonase® Allergy Relief for over-the-counter relief in Canada. Press Release. August 26, 2016.
- Data on file. GlaxoSmithKline. 2016.